QUADIENT SA: Availability of the share buyback program description
Paris, June 17, 2025
Quadient (Euronext Paris: QDT) announces the availability of the description of its share buyback program, launched by the Board of Directors on June 13, 2025, following the authorization granted by the Ordinary General Meeting held on June 13, 2025 (17th resolution).
This description has been prepared in compliance with the provisions of Articles 241-1 et seq. of the General Regulation of the Autorité des Marchés Financiers (AMF), Articles L. 22-10-62 et seq. of the French Commercial Code, as well as the provisions of European Regulation No. 596/2014 and Delegated Regulation No. 2016/1052.
This document can be consulted on the Company's investor relations website (https://invest.quadient.com/en/quadient-investor-relations).
For more information, please contact:
Anne-Sophie Jugean, Quadient+33 (0)1 45 36 30 24as.jugean@quadient.comfinancial-communication@quadient.com
Or visit our website: https://invest.quadient.com/
Attachment
PDF
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
13 hours ago
- Business Wire
Rithm Capital Corp. Declares Second Quarter 2025 Common and Preferred Dividends
NEW YORK--(BUSINESS WIRE)--Rithm Capital Corp. (NYSE:RITM, 'Rithm Capital' or the 'Company') announced today that its Board of Directors (the 'Board') has declared second quarter 2025 common and preferred stock dividends. Common Stock Dividend The Board declared a dividend of $0.25 per share of common stock for the second quarter 2025. The second quarter common stock dividend is payable on July 31, 2025, to shareholders of record on June 30, 2025. Preferred Stock Dividends In accordance with the terms of Rithm Capital's Series A Cumulative Redeemable Preferred Stock ('Series A'), the Board declared a Series A dividend for the second quarter 2025 of $0.6638017 per share, which reflects a rate of 10.390%. The Series A Preferred Stock accrue dividends at a floating rate equal to three-month CME SOFR (plus a spread adjustment of 0.261%) plus a spread of 5.802%. In accordance with the terms of Rithm Capital's Series B Cumulative Redeemable Preferred Stock ('Series B'), the Board declared a Series B dividend for the second quarter 2025 of $0.6534517 per share, which reflects a rate of 10.228%. The Series B Preferred Stock accrue dividends at a floating rate equal to three-month CME SOFR (plus a spread adjustment of 0.261%) plus a spread of 5.640%. In accordance with the terms of Rithm Capital's Series C Cumulative Redeemable Preferred Stock ('Series C'), the Board declared a Series C dividend for the second quarter 2025 of $0.6105823 per share, which reflects a rate of 9.557%. The Series C Preferred Stock accrue dividends at a floating rate equal to three-month CME SOFR (plus a spread adjustment of 0.261%) plus a spread of 4.969%. In accordance with the terms of Rithm Capital's 7.000% Series D Fixed-Rate Reset Cumulative Redeemable Preferred Stock ('Series D'), the Board declared a Series D dividend for the second quarter 2025 of $0.4375000 per share. Dividends for the Series A, Series B, Series C and Series D are payable on August 15, 2025, to preferred shareholders of record on August 1, 2025. ABOUT RITHM CAPITAL Rithm Capital Corp. is a global, multi-dimensional asset manager with significant experience managing credit and real estate assets. The firm combines deep institutional expertise with an entrepreneurial culture that drives innovation and disciplined growth across multiple market segments. Rithm's integrated investment platform spans residential and commercial lending, mortgage servicing rights (MSRs) and structured credit. Through subsidiaries such as Newrez, Genesis Capital, and Sculptor Capital Management, Rithm has established a unique owner-operator model, capable of sourcing, financing, and actively managing debt and equity investments, to drive value for shareholders and fund investors. Source: Rithm Capital Corp.
Yahoo
21 hours ago
- Yahoo
EASTPLATS ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
VANCOUVER, BC, June 18, 2025 /CNW/ - Eastern Platinum Limited (TSX: ELR) (JSE: EPS) ("Eastplats" or the "Company") announces the voting results of the Company's 2025 Annual General and Special Meeting of Shareholders held on June 17, 2025 (the "Meeting"). A total of 122,533,921 common shares were voted at the Meeting, representing 60.51% of the votes attached to all the outstanding common shares of the Company. Detailed results of the vote held at the Meeting are set out below:BusinessOutcome ofVoteVotes ForVotes Against VotesWithheld 1. To set the number of Directorsat 5Approved122,379,825 (99.87 %)154,096 (0.13 %) 2. Resolution electing: (a) Dr. Bielin Shi;Approved10,654,809 (8.82%) 110,153,359 (91.18%)(b) Xin (Alex) Guan;Approved120,579,533 (99.81%) 228,635 (0.19%)(c) Changyu (Charlie) Liu;Approved120,573,767 (99.81%) 234,401 (0.19%)(d) Lisa Ng; andApproved120,584,083 (99.82%) 224,085 (0.18%)(e) Eason Cong ChenApproved120,573,667 (99.81%) 234,501 (0.19%)as directors of the Company. 3. Resolution appointingDavidson & Company LLP, asauditors of the Company forthe ensuing year andauthorizing the directors of theCompany to fix (99.86%) 173,447 (0.14%)4. Resolution approving theunallocated options, rights andother entitlements issuableunder the Company's StockOption Plan for a further (99.46%)652,249 (0.54%)Based on the voting results, all of the nominees proposed as directors and listed in the management information circular dated May 6, 2025 (the "Circular") were elected as directors of Eastplats at the Meeting in accordance with applicable corporate law. However, one director, Dr. Bielin Shi, had more votes withheld than were voted in their favour of their appointments to the Board. As a result, in accordance with the Company's Majority Voting Policy (the "Policy"), Dr. Shi has tendered his resignation from the Board of Directors of the Company (the "Board"), effective upon acceptance by the Board. The Board will refer such resignations to the Corporate Governance and Compensation Committee (the "Committee") for consideration on whether or not to accept the resignations submitted by Dr. Shi. In accordance with the Policy, the Board shall accept such resignation unless the Committee determines that there are exceptional circumstances relating to the composition of the Board or the voting results that should delay the acceptance of such resignation or justify rejecting such resignation. The Board will issue a news release with its decision. At the Meeting, the unallocated options, rights or other entitlements issuable under Eastplats' Stock Option Plan have been authorized for three further years and Davidson & Company LLP was also re-appointed as auditors of Eastplats. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. SOURCE Eastern Platinum Ltd. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
a day ago
- Business Upturn
SINOVAC Announces New Board Member
Beijing, China: Sinovac Biotech Ltd. (Nasdaq: SVA) ('SINOVAC' or the 'Company'), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the 'Board') and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Board to fill the vacancy created by such resignation under the laws of Antigua and Barbuda. Mr. Hsu has also been elected as a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board. Mr. Hsu is a General Partner and Portfolio Manager at OrbiMed, one of the world's largest dedicated healthcare investment firms, managing over $17 billion in assets. Mr. Hsu brings extensive investment experience in the biotechnology industry and China. He joined OrbiMed in 2002 and has been a Portfolio Manager since 2005, leading the public equity team's biotech and emerging markets efforts. He has been responsible for overseeing the firm's public equity investments in China since 2009 and the firm's investment in SINOVAC since 2013. Prior to joining OrbiMed, Mr. Hsu worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. He received an A.B. degree summa cum laude from Harvard University and holds an M.B.A. from Harvard Business School. Following this appointment, the Board consists of four members, including Dr. Chiang Li (Chairman), Mr. Yuk Lam Lo, Mr. Sven H. Borho, CFA, and Mr. Hsu. The Audit Committee of the Board consists of three members, including Mr. Borho, Mr. Lo and Mr. Hsu. The Compensation Committee and the Corporate Governance and Nominating Committee of the Board each consists of Dr. Li, Mr. Lo and Mr. Hsu. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under 'Category 1 Preventative Biological Products' and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company's website at View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
